AKBAHIGH SIGNALFINANCIAL10-K

AKBA substantially reduced losses while meaningfully expanding R&D investment and growing total assets by over 70%.

The dramatic improvement in net losses combined with increased R&D spending suggests the company is investing heavily in development while achieving better operational efficiency or revenue growth. However, the addition of new risk language around profitability uncertainty and regulatory compliance indicates management is flagging heightened operational challenges despite the improved financial performance.

Comparing 2026-02-26 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

AKBA's financial position strengthened considerably with total assets growing 70.6% to $376.6M and net losses substantially reduced from -$69.4M to -$5.3M. The company meaningfully expanded R&D spending by 65.6% to $62.4M while accounts receivable grew 36.8%, suggesting increased commercial activity. Total liabilities increased 27.5% and debt rose 24.7%, indicating controlled leverage expansion to fund growth initiatives.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+92.3%
-$69.4M→-$5.3M

Net income grew 92.3% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+70.6%
$220.7M→$376.6M

Asset base grew 70.6% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
+65.6%
$37.7M→$62.4M

R&D investment increased 65.6% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
+36.8%
$34.4M→$47.0M

Receivables surged 36.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Total Liabilities
Balance Sheet
+27.5%
$269.9M→$344.0M

Liabilities increased 27.5% — monitor debt-to-equity ratio and interest coverage.

Total Debt
Balance Sheet
+24.7%
$38.7M→$48.3M

Debt rose 24.7% — additional borrowing for investment or operations; monitor coverage ratios.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-13
ADDED
We have incurred significant losses since our inception, and anticipate that we will continue to incur losses and cannot guarantee when, if ever, we will become and remain profitable.
Our Royalty Interest Acquisition Agreement contains various covenants and other provisions, which, if violated, could materially adversely affect our financial condition.
The commercialization of ferric citrate, and our current and potential future efforts with respect to the development and commercialization of our products and product candidates outside of the United States, or U.S.
We may not be able to obtain orphan drug exclusivity for praliciguat or any potential future product candidates that we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.
We are subject to complex regulatory schemes that require significant resources to ensure compliance and our failure to comply with applicable laws could subject us to government scrutiny or enforcement, potentially resulting in costly investigations, fines, penalties or sanctions, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.
+7 more — sign up free →
REMOVED
We have incurred significant losses since our inception, and anticipate that we will continue to incur losses and cannot guarantee when, if ever, we will become profitable or attain positive cash flows.
Our Royalty Interest Acquisition Agreement with HealthCare Royalty Partners IV, L.P.
contains various covenants and other provisions, which, if violated, could materially adversely affect our financial condition.
The commercialization of ferric citrate, branded as Riona in Japan, Vafseo in Europe, Japan and other territories where it is approved, and our current and potential future efforts with respect to the development and commercialization of our products and product candidates outside of the United States, or U.S.
Products approved for marketing are subject to extensive post-marketing regulatory requirements, including post-approval pediatric studies for Auryxia and Vafseo, and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties, including withdrawal of marketing approval, if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, or product candidates, when and if approved.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →